{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T22:17:31Z","timestamp":1779142651713,"version":"3.51.4"},"reference-count":61,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.dsx.2022.102528","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T02:06:47Z","timestamp":1654135607000},"page":"102528","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Rising cost of insulin: A deterrent to compliance in patients with diabetes mellitus"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4813-7335","authenticated-orcid":false,"given":"Abdul Hamid","family":"Zargar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prasanna Kumar","family":"K M","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sreenivasa","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay","family":"Negalur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajesh","family":"Rajput","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashu","family":"Rastogi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Banshi","family":"Saboo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surendra Kumar","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakesh","family":"Sahay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.R.","family":"Aravind","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shehla","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mangesh","family":"Tiwaskar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahu","family":"Ingole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Kamble","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.dsx.2022.102528_bib1","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2018-000519","article-title":"GOAL study: clinical and non-clinical predictive factors for achieving glycemic control in people with type 2 diabetes in real clinical practice","volume":"6","author":"Al Mansari","year":"2018","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"9-a","key":"10.1016\/j.dsx.2022.102528_bib2","first-page":"S5","article-title":"Burden of illness in type 2 diabetes mellitus","volume":"24","author":"Cannon","year":"2018","journal-title":"J\u00a0Manag Care Spec Pharm"},{"issue":"8","key":"10.1016\/j.dsx.2022.102528_bib3","first-page":"609","article-title":"Medical claim cost impact of improved diabetes control for Medicare and commercially insured patients with type 2 diabetes","volume":"19","author":"Fitch","year":"2013","journal-title":"J\u00a0Manag Care Pharm"},{"issue":"1","key":"10.1016\/j.dsx.2022.102528_bib4","first-page":"e62","article-title":"Relationship of diabetes complications severity to healthcare utilization and costs among Medicare Advantage beneficiaries","volume":"21","author":"Hazel-Fernandez","year":"2015","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.dsx.2022.102528_bib5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00125-008-1157-y","article-title":"Medical management of hyperglycemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes","volume":"52","author":"Nathan","year":"2009","journal-title":"Diabetologia"},{"issue":"10 Spec No","key":"10.1016\/j.dsx.2022.102528_bib6","article-title":"JDRF's Kowalski sees hope in bipartisan support for insulin pricing reform","volume":"25","author":"Smith","year":"2019","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.dsx.2022.102528_bib7","first-page":"1","article-title":"Insulin cost and pricing trends","author":"Hayes","year":"2020","journal-title":"Am Action Forum"},{"issue":"6","key":"10.1016\/j.dsx.2022.102528_bib8","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.2337\/dci18-0019","article-title":"Insulin access and affordability working group. Insulin access and affordability working group: conclusions and recommendations","volume":"41","author":"Cefalu","year":"2018","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.dsx.2022.102528_bib9","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s40273-015-0268-9","article-title":"The economic costs of type 2 diabetes: a global systematic review","volume":"33","author":"Seuring","year":"2015","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.dsx.2022.102528_bib10","series-title":"Diabetes atlas","year":"2019"},{"key":"10.1016\/j.dsx.2022.102528_bib11","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12992-014-0080-x","article-title":"The economic burden of diabetes in India: a review of the literature","volume":"10","author":"Yesudian","year":"2014","journal-title":"Glob Health"},{"issue":"3","key":"10.1016\/j.dsx.2022.102528_bib12","first-page":"473","article-title":"Economic analysis of diabetes care","volume":"125","author":"Kapur","year":"2007","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.dsx.2022.102528_bib13","first-page":"667","article-title":"Direct cost of ambulatory care of type 2 diabetes in the middle and high income group populace of Delhi: the DEDICOM survey","volume":"56","author":"Kumar","year":"2008","journal-title":"J\u00a0Assoc Phys India"},{"issue":"956","key":"10.1016\/j.dsx.2022.102528_bib14","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1136\/pgmj.2004.024299","article-title":"Cost of ambulatory care of diabetes mellitus: a study from north India","volume":"81","author":"Grover","year":"2005","journal-title":"Postgrad Med"},{"key":"10.1016\/j.dsx.2022.102528_bib15","first-page":"1","article-title":"Economic menace of diabetes in India: a systematic review","author":"Oberoi","year":"2020","journal-title":"Int J Diabetes Dev Ctries"},{"issue":"6","key":"10.1016\/j.dsx.2022.102528_bib16","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S2213-8587(17)30097-9","article-title":"The global economic burden of diabetes in adults aged 20-79 years: a cost-of-illness study","volume":"5","author":"Bommer","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.dsx.2022.102528_bib17","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.2337\/diab.44.11.1249","article-title":"Prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease","volume":"44","year":"1995","journal-title":"Diabetes"},{"key":"10.1016\/j.dsx.2022.102528_bib18","first-page":"717","article-title":"Diab-care Asia-India study: diabetes care in India-current status","volume":"49","author":"Raheja","year":"2001","journal-title":"J\u00a0Assoc Phys India"},{"issue":"2","key":"10.1016\/j.dsx.2022.102528_bib19","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.mjafi.2014.10.008","article-title":"The ABC of diabetes. How many patients are able to achieve the goal laid down by American Diabetes Association?","volume":"71","author":"Menon","year":"2015","journal-title":"Med J Armed Forces India"},{"issue":"10","key":"10.1016\/j.dsx.2022.102528_bib20","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.2337\/dc09-0653","article-title":"Insulin-based versus triple oral therapy for newly diagnosed type 2 diabetes: which is better?","volume":"32","author":"Ildiko","year":"2009","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.dsx.2022.102528_bib21","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1089\/dia.2013.0081","article-title":"Clinical evidence for the earlier initiation of insulin therapy in type 2 diabetes","volume":"15","author":"Owens","year":"2013","journal-title":"Diabetes Technol Therapeut"},{"key":"10.1016\/j.dsx.2022.102528_bib22","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1007\/s13300-020-00855-5","article-title":"Rationale for timely insulin therapy in type 2 diabetes within the framework of individualised treatment: 2020 update","volume":"11","author":"Hanefeld","year":"2020","journal-title":"Diabetes Ther"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.dsx.2022.102528_bib23","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.2337\/dc21-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes\u20142021","volume":"44","author":"American Diabetes Association","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2022.102528_bib24","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2337\/diacare.28.2.254","article-title":"Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes","volume":"28","author":"Janka","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2022.102528_bib25","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40545-019-0190-1","article-title":"Challenges constraining availability and affordability of insulin in Bengaluru region (Karnataka, India): evidence from a mixed-methods study","volume":"12","author":"Satheesh","year":"2019","journal-title":"J\u00a0of Pharm Policy and Pract"},{"key":"10.1016\/j.dsx.2022.102528_bib26","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/S0140-6736(03)13375-2","article-title":"25 years of the WHO essential medicines lists: progress and challenges","volume":"361","author":"Laing","year":"2003","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.dsx.2022.102528_bib28","doi-asserted-by":"crossref","first-page":"412","DOI":"10.4103\/2230-8210.180006","article-title":"National list of essential medicines, 2015: endocrinology perspective","volume":"20","author":"Kalra","year":"2016","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.dsx.2022.102528_bib30","unstructured":"Medicines in India - brookings institution. https:\/\/www.brookings.edu\/wp-content\/uploads\/2020\/03\/Medicines-in-India_for-web-1.pdf. [Accessed 30 August 2021]."},{"issue":"2","key":"10.1016\/j.dsx.2022.102528_bib31","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1111\/1475-6773.12700","article-title":"Effect of out-of-pocket cost on medication initiation, adherence, and persistence among patients with type 2 diabetes: the diabetes study of Northern California (DISTANCE)","volume":"53","author":"Karter","year":"2018","journal-title":"Health Serv Res"},{"key":"10.1016\/j.dsx.2022.102528_bib32","doi-asserted-by":"crossref","first-page":"370","DOI":"10.4103\/2230-8210.129715","article-title":"Current status of management, control, complications and psychosocial aspects of patients with diabetes in India: results from the DiabCare India 2011 Study","volume":"18","author":"Mohan","year":"2014","journal-title":"Indian J Endocrinol Metab"},{"issue":"Supplement 1","key":"10.1016\/j.dsx.2022.102528_bib33","article-title":"Antidiabetes drug prescription in Indian scenario-A cross-sectional analysis from a large, Pan India database of the Apollo sugar Clinics","volume":"67","author":"Seshadri","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.dsx.2022.102528_bib34","doi-asserted-by":"crossref","first-page":"40","DOI":"10.4103\/ijem.IJEM_646_18","article-title":"Drug prescription patterns and cost analysis of diabetes therapy in India: audit of an endocrine practice","volume":"23","author":"Singla","year":"2019","journal-title":"Indian J Endocr Metab"},{"issue":"Supplement 1","key":"10.1016\/j.dsx.2022.102528_bib35","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.2337\/dc18-S008","article-title":"Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2018","volume":"41","author":"American Diabetes Association","year":"2018","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.dsx.2022.102528_bib36","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2337\/diaclin.34.2.97","article-title":"Treatment approach to patients with severe insulin resistance","volume":"34","author":"Church","year":"2016","journal-title":"Clin Diabetes"},{"issue":"3","key":"10.1016\/j.dsx.2022.102528_bib37","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S2213-8587(17)30041-4","article-title":"Strategies to improve the affordability of insulin in the USA","volume":"5","author":"Luo","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.dsx.2022.102528_bib38","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.glohj.2019.11.001","article-title":"Containing the rising cost of insulin: select policy recommendations","volume":"3","author":"Titus","year":"2019","journal-title":"J\u00a0Dis Global Health"},{"issue":"12","key":"10.1016\/j.dsx.2022.102528_bib39","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1089\/dia.2017.0286","article-title":"Rising costs of drug\/insulin treatment for diabetes: a perspective from India","volume":"19","author":"Misra","year":"2017","journal-title":"Diabetes Technol Therapeut"},{"issue":"3","key":"10.1016\/j.dsx.2022.102528_bib40","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(15)00521-5","article-title":"Constraints and challenges in access to insulin: a global perspective","volume":"4","author":"Beran","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.dsx.2022.102528_bib41","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1001\/jamainternmed.2018.5008","article-title":"Cost-related insulin underuse among patients with diabetes","volume":"179","author":"Herkert","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"2","key":"10.1016\/j.dsx.2022.102528_bib42","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2337\/diacare.27.2.384","article-title":"Problems paying out-of-pocket medication costs among older adults with diabetes","volume":"27","author":"Piette","year":"2004","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.dsx.2022.102528_bib43","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jama.285.4.421","article-title":"Adverse events associated with prescription drug cost-sharing among poor and elderly persons","volume":"285","author":"Tamblyn","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.dsx.2022.102528_bib44","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.2147\/PPA.S106821","article-title":"Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors","volume":"10","author":"Polonsky","year":"2016","journal-title":"Patient Prefer Adherence"},{"issue":"7","key":"10.1016\/j.dsx.2022.102528_bib45","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1185\/03007995.2015.1053048","article-title":"Meta-analysis of studies examining medication adherence, persistence, and discontinuation of oral antihyperglycemic agents in type 2 diabetes","volume":"31","author":"Iglay","year":"2015","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"10.1016\/j.dsx.2022.102528_bib46","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.clinthera.2011.01.019","article-title":"A\u00a0review of diabetes treatment adherence and the association with clinical and economic outcomes","volume":"33","author":"Asche","year":"2011","journal-title":"Clin Therapeut"},{"issue":"6","key":"10.1016\/j.dsx.2022.102528_bib47","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/j.1524-4733.2009.00539.x","article-title":"Costs of medication nonadherence in patients with diabetes mellitus: a systematic review and critical analysis of the literature","volume":"12","author":"Salas","year":"2009","journal-title":"Value Health"},{"issue":"13 Suppl","key":"10.1016\/j.dsx.2022.102528_bib48","first-page":"S247","article-title":"Strategies for addressing the cost of nonadherence in diabetes","volume":"23","author":"Morello","year":"2017","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.dsx.2022.102528_bib49","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2017-000429","article-title":"Medication adherence and glycemic control among newly diagnosed diabetes patients","volume":"5","author":"Lin","year":"2017","journal-title":"BMJ Open Diab Res Care"},{"issue":"Suppl 27","key":"10.1016\/j.dsx.2022.102528_bib50","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/pedi.12701","article-title":"ISPAD clinical practice consensus guidelines 2018: diabetic ketoacidosis and the hyperglycemic hyperosmolar state","volume":"19","author":"Wolfsdorf","year":"2018","journal-title":"Pediatr Diabetes"},{"key":"10.1016\/j.dsx.2022.102528_bib51","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2337\/diacare.18.4.483","article-title":"Diabetes in urban African-Americans. I. Cessation of insulin therapy is the major precipitating cause of diabetic ketoacidosis","volume":"18","author":"Musey","year":"1995","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.dsx.2022.102528_bib52","first-page":"108","article-title":"Association between glycemic control and shortterm healthcare costs among commercially insured diabetes patients in the United States","volume":"14","author":"Aagren","year":"2011","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.dsx.2022.102528_bib53","first-page":"176","article-title":"Direct medical costs of complications of diabetes in the United States: estimates for event-year and annual state costs (USD 2012)","volume":"17","author":"Ward","year":"2014","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.dsx.2022.102528_bib54","unstructured":"U.S. Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product. Updated April 2015. Available at: https:\/\/www.fda.gov\/media\/82647\/download [Accessed on 18 January 2022]."},{"issue":"2","key":"10.1016\/j.dsx.2022.102528_bib55","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1177\/1932296815605337","article-title":"Biosimilar insulin and costs: what can we expect?","volume":"10","author":"Heinemann","year":"2015","journal-title":"J\u00a0Diabetes Sci Technol"},{"issue":"10146","key":"10.1016\/j.dsx.2022.102528_bib57","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0140-6736(18)31730-6","article-title":"Biosimilars for insulin: a cost-saving alternative?","volume":"392","author":"McCall","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.dsx.2022.102528_bib58","unstructured":"Tata 1mg. Cost in INR as available on https:\/\/www.1mg.com\/. [Accessed on 20 April 2022]."},{"issue":"10","key":"10.1016\/j.dsx.2022.102528_bib59","article-title":"Biosimilar insulin could offer patients cost-saving options","volume":"25","author":"Karlovitch","year":"2019","journal-title":"Am J Manag Care"},{"issue":"6","key":"10.1016\/j.dsx.2022.102528_bib60","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1111\/jdi.12843","article-title":"Cross-sectional survey of biosimilar insulin utilization in Asia: the joint Asia diabetes evaluation program","volume":"9","author":"Gani","year":"2018","journal-title":"J\u00a0Diabetes Investig"},{"issue":"1","key":"10.1016\/j.dsx.2022.102528_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.13189\/adm.2020.080101","article-title":"Six months comparative evaluation of efficacy and safety of wockhardt's biosimilar insulin glargine (Glaritus\u00ae) with reference insulin glargine (Lantus\u00ae) in type 2 diabetes mellitus in India: results of interim analysis","volume":"8","author":"Sharma","year":"2020","journal-title":"Adv Diabet Metabol"},{"issue":"4","key":"10.1016\/j.dsx.2022.102528_bib62","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1210\/clinem\/dgaa817","article-title":"Addressing insulin access and affordability: an endocrine society position statement","volume":"106","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.dsx.2022.102528_bib63","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4103\/2230-8210.164033","article-title":"Biosimilar insulins: informed choice for South Asia","volume":"20","author":"Kalra","year":"2016","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.dsx.2022.102528_bib64","unstructured":"Seshiah V, Das AK, Sethi BK, Moses CR, Kumar A, Viswanathan V, et\u00a0al. Biopharmaceuticals and biosimilars: a consensus statement. Medicine update, 5, 237\u2013241. Available at: http:\/\/www.apiindia.org\/medicine_update_2013\/chap52.pdf. [Accessed on 30 August 2021]."}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402122001424?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402122001424?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:19:30Z","timestamp":1761729570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402122001424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":61,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S1871402122001424"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2022.102528","relation":{},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rising cost of insulin: A deterrent to compliance in patients with diabetes mellitus","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2022.102528","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd on behalf of Diabetes India.","name":"copyright","label":"Copyright"}],"article-number":"102528"}}